No- 10. Osilodrostat- (ISTURISA)- (Mar 2020)

PATIENT COUNSELING INFORMATION

Advise patients to read the FDA-approved patient labeling (Patient Information).

Handling of Orally Disintegrating Tablets- Packaging-                                      Instruct patients not to remove the blister from the outer aluminum pouch until ready to use the orally disintegrating tablet inside 

Hypersensitivity Reactions-                                                                                  Inform patients about the signs and symptoms of hypersensitivity reactions and that these reactions can occur days after administration of NURTEC ODT.

Advise patients to contact their healthcare provider immediately if signs or symptoms of hypersensitivity reactions occur.

Manufactured for: Biohaven Pharmaceuticals, Inc. New Haven, CT 06510 USA © 2020, Biohaven Pharmaceuticals Inc. NURTEC and Biohaven are trademarks of Biohaven Pharmaceutical Holding Company Ltd